BioSig AI Sciences Selected for NVIDIA Inception Partnership Program

BioSig AI Sciences (BSAI), a subsidiary of medical technology company, BioSig Technologies (Nasdaq: BSGM), has been selected to join NVIDIA Inception (Nasdaq: NVDA), a program designed to partner with companies revolutionizing industries with advancements in artificial intelligence (AI) and data sciences. The company’s share price rose nearly 20% in intra-day trading following the news.

Ken Londoner, Chairman, CEO and Founder of BioSig, said, “We are thrilled to join an elite group of AI-centric technology companies leading the evolution of machine learning and AI across industries.”


BSAI is training its AI platform with electrocardiogram and intracardiac electrogram data from BioSig’s patented PURE EP™ Platform.

BioSig stated that as BAIS advances research and development of its AI medical device platform, it intends to draw on NVIDIA’s wealth of resources including developer application frameworks and domain-specific AI computing for building medical devices.

NVIDIA Inception helps leading emerging-growth companies during critical stages of product development, prototyping and deployment.

Partners are qualified to receive engineering guidance, technical training, hardware and software support, co-marketing, and exposure to the NVIDIA investment community.

The company’s PURE EP™ Platform has been used in more than 3,500 procedures to date and featured in peer-reviewed clinical research.

About BioSig Technology 

BioSig is an advanced medical technology company bringing never-before-seen insights to the treatment of cardiovascular arrhythmias. Through collaboration with physicians, experts, and healthcare leaders across the field of electrophysiology (EP), BioSig is committed to addressing healthcare’s biggest priorities—saving time, saving costs, and saving lives.

The Company’s first product, the PURE EP™ Platform, an FDA 510(k) cleared non-invasive class II device, provides superior, real-time signal visualization allowing physicians to perform insight-based, highly targeted cardiac ablation procedures with increased procedural efficiency and efficacy.

Share This Article


About the Author

BioSig AI Sciences Selected for NVIDIA Inception Partnership Program

Editor Prism MarketView